The North American market for GERD drugs and devices is conjectured to grow with a CAGR of 0.78% during the forecast period of 2019-2027. This region accounts for the largest market for GERD drugs and devices globally, thanks to the larger number of patients diagnosed with heartburn that leads to GERD which further requires acid reducing and neutralizing drugs.

NORTH AMERICA  GERD DRUGS AND DEVICES MARKET FORECAST 2019-2026

Request free sample

The North American market for GERD drugs and devices is conjectured to grow with a CAGR of 0.78% during the forecast period of 2019-2027. This region accounts for the largest market for GERD drugs and devices globally, thanks to the larger number of patients diagnosed with heartburn that leads to GERD which further requires acid reducing and neutralizing drugs.

The rise in initiatives for awareness, education and funding for research on reflux and GERD are also expected to drive the market growth in the United States.

According to studies, GERD is the most prevalent acid associated disorder in Canada, which pertains to its largest revenue gained off the said market in the North American region. Here too, the rise in awareness and preference of self-medication concerning GERD and other acid-related disorders are primarily driving the market growth in Canada.

Some of the key companies are focusing on newer products to increase their portfolio size and also on regional expansion. Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. & Takeda Pharmaceuticals Company Ltd. are such market players.

 

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • ANTACIDS DRUG CLASS HOLDS THE LARGEST MARKET SHARE
        • BRAVO SYSTEM DEVICES ARE WIDELYUSED
    1. MARKET DYNAMICS
      • MARKET SCOPE & DEFINITION
      • MARKET DRIVERS
        • GROWING TREND OF SELF-MEDICATION
        • INCREASING AWARENESS ABOUT GERD
        • INCREASING OCCURRENCE OF GERD DISORDERS
        • CHANGES IN LIFESTYLE
      • MARKET RESTRAINTS
        • PATENT EXPIRY
        • ADVERSE EFFECT OF PROTON PUMP INHIBITORS AND OTHER DRUGS
        • PROTON PUMP INHIBITOR RESISTANCE
      • MARKET OPPORTUNITIES
        • INCREASED PRACTICE OF GENERICS AND OTC DRUGS
        • COST-EFFECTIVE OTC DRUGS
        • OVERUSE OF MEDICATION AND DIETARY SUPPLEMENTS
      • MARKET CHALLENGES
        • USE OF COMPLEMENTARY AND ALTERNATIVE TREATMENTS
        • PROBABILITY OF BUYING COUNTERFEIT DRUGS
      • MARKET BY DRUGS DOSAGE FORM
      • MARKET BY ROUTE OF ADMINISTRATION OF DRUGS
    2. MARKET BY DRUGS AND DEVICES
      • DRUG CLASS
        • ANTACIDS
        • H2 RECEPTOR BLOCKERS
        • PROTON PUMP INHIBITORS (PPI)
        • PRO-KINETIC AGENTS
      • DEVICES
        • DIGITRAPPER
        • BRAVO SYSTEM
        • STRETTA
        • LINX REFLUX MANAGEMENT SYSTEM
        • MUSE (MEDIGUS ULTRASONIC SURGICAL ENDOSTAPLER) SYSTEM
        • OTHER DEVICES
    1. KEY ANALYTICS
      • PORTER’S FIVE FORCE MODEL
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE
        • BARGAINING POWER OF SUPPLIERS
        • BARGAINING POWER OF BUYERS
        • THREAT OF COMPETITIVE RIVALRY
      • PIPELINE DRUGS
      • REGULATORY FRAMEWORK
      • PATENT ANALYSIS
      • OPPORTUNITY MATRIX
    2. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • THE UNITED STATES
        • CANADA
    1. COMPETITIVE LANDSCAPE
      • MARKET SHARE ANALYSIS
      • COMPANY PROFILES
        • ABBOTT LABORATORIES.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • ASTRAZENECA
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • BAUSCH HEALTH (FORMERLY VALEANT PHARMACEUTICALS INTERNATIONAL, INC.)
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • BOSTON SCIENTIFIC CORPORATION
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • CEMPRA INC. (MERGED WITH MELINTA)
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • DAEWOONG CO. LTD.
          • COMPANY PROFILES
          • PRODUCT PORTFOLIO
          • STRATEGIC INITIATIVES
        • EISAI INC
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • GLAXOSMITHKLINE
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • IRONWOOD PHARMACEUTICALS, INC.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • JOHNSON & JOHNSON
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • MERCK & CO., INC.
          • COMPANY PROFILES
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • NOVARTIS
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • PFIZER, INC.
          • COMPANY PROFILES
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • RAQUAL IA PHARMA INC.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • STRATEGIC INITIATIVES
        • TAKEDA PHARMACEUTICALS COMPANY LIMITED
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES

    LIST OF TABLES

    TABLE 1       NORTH AMERICA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    TABLE 2       NORTH AMERICA GERD DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2019-2027 ($ MILLION)

    TABLE 3       NORTH AMERICA DRUG CLASS MARKET BY TYPES 2019-2027 ($ MILLION)

    TABLE 4       NORTH AMERICA DRUG CLASS MARKET 2019-2027 ($ MILLION)

    TABLE 5       NORTH AMERICA ANTACIDS MARKET 2019-2027 ($ MILLION)

    TABLE 6       NORTH AMERICA H2 RECEPTOR BLOCKERS MARKET 2019-2027 ($ MILLION)

    TABLE 7       NORTH AMERICA H2 RECEPTOR BLOCKERS MARKET BY TYPES 2019-2027 ($ MILLION)

    TABLE 8       NORTH AMERICA PROTON PUMP INHIBITORS (PPI) MARKET 2019-2027 ($ MILLION)

    TABLE 9       NORTH AMERICA PROTON PUMP INHIBITORS (PPI) MARKET BY TYPES 2019-2027 ($ MILLION)

    TABLE 10     NORTH AMERICA PRO-KINETIC AGENTS MARKET 2019-2027 ($ MILLION)

    TABLE 11     NORTH AMERICA DEVICES MARKET BY TYPES 2019-2027 ($ MILLION)

    TABLE 12     NORTH AMERICA DEVICES MARKET 2019-2027 ($ MILLION)

    TABLE 13     NORTH AMERICA DIGITRAPPER MARKET 2019-2027 ($ MILLION)

    TABLE 14     NORTH AMERICA BRAVO SYSTEM MARKET 2019-2027 ($ MILLION)

    TABLE 15     NORTH AMERICA STRETTA (MEDERITHERAPEUTICS) MARKET 2019-2027 ($ MILLION)

    TABLE 16     NORTH AMERICA LINX® REFLUX MANAGEMENT SYSTEM (TORAX MEDICAL) MARKET 2019-2027 ($ MILLION)

    TABLE 17     NORTH AMERICA MUSE™ (MEDIGUS ULTRASONIC SURGICAL ENDOSTAPLER) SYSTEM MARKET 2019-2027 ($ MILLION)

    TABLE 18     NORTH AMERICA OTHER DEVICES MARKET 2019-2027 ($ MILLION)

    TABLE 19     NORTH AMERICA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    TABLE 20     NORTH AMERICA GERD DRUGS AND DEVICES MARKET BY COUNTRY 2019-2027 ($ MILLION)

    LIST OF FIGURES

    FIGURE 1     NORTH AMERICA GERD DRUGS AND DEVICES MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)

    FIGURE 2     NORTH AMERICA GERD DRUGS AND DEVICES MARKET SHARE BY DRUGS AND DEVICES 2017 & 2027 (%)

    FIGURE 3     PORTER’S FIVE FORCE MODEL

    FIGURE 4     NORTH AMERICA GERD DRUGS AND DEVICES MARKET REGIONAL OUTLOOK 2018 & 2027 (%)

    FIGURE 5     THE UNITED STATES GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    FIGURE 6     CANADA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    FIGURE 7     GERD PPIS DRUGS PROVIDER COMPANY MARKET SHARE 2017 (%)

    1. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • THE UNITED STATES
        • CANADA
    1. MARKET BY DRUGS AND DEVICES
      • DRUG CLASS
        • ANTACIDS
        • H2 RECEPTOR BLOCKERS
        • PROTON PUMP INHIBITORS (PPI)
        • PRO-KINETIC AGENTS
      • DEVICES
        • DIGITRAPPER
        • BRAVO SYSTEM
        • STRETTA
        • LINX REFLUX MANAGEMENT SYSTEM
        • MUSE (MEDIGUS ULTRASONIC SURGICAL ENDOSTAPLER) SYSTEM
        • OTHER DEVICES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type